JOHN M. BENNETT, M.D.; STEVEN D. REICH, M.D.
Bleomycin was approved by the Food and Drug Administration in 1975 for therapy against squamous cell carcinomas, testicular cancers, and malignant lymphomas. An extensive bibliography on this drug indicates that there is little evidence of activity against other malignancies. Although initially used exclusively as a single agent, bleomycin has been considered recently for use in combination chemotherapy. Because of associated toxicity involving the lung and mucous membranes, bleomycin should be used cautiously by physicians, particularly in noninvestigational settings.
BENNETT JM, REICH SD. Drugs Five Years Later: Bleomycin. Ann Intern Med. ;90:945–948. doi: 10.7326/0003-4819-90-6-945
Download citation file:
Published: Ann Intern Med. 1979;90(6):945-948.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use